In celebration of World Cancer Day 2022, the British Society for Immunology is pleased to collect together recent articles from our official journals Clinical & Experimental Immunology and Immunotherapy Advances which highlight cutting-edge research into cancer immunology and immunotherapy.
Knowledge of the mechanisms by which the immune system interacts with cancer as it develops is increasing rapidly. From this field, cancer immunotherapy has emerged as one of the most exciting and promising approaches to treating cancer. These developments have translated into medical breakthroughs for many cancer patients, although the high prevalence of non-responders and adverse reactions reveals that there are still significant challenges to overcome.
This collection features research and reviews on key topics in the field topics such as CAR-T cell therapies, microRNAs, regulatory T cells and checkpoint inhibition-induced adverse events. All articles have been published in 2020 and 2021 and are free to read online.
We hope you enjoy reading this collection of articles and we encourage you to share this using the hashtag #WorldCancerDay and looping in @CEIjournal and @IMTadvances.
We’ve just launched a new Open Access journal for cellular and molecular immunology, Discovery Immunology!
The journal will be edited by leading immunologist Professor Simon Milling (University of Glasgow), with support from six international Senior Editors and a growing Editorial Board. Visit Discovery Immunology’s official website to explore the scope and follow the journal on Twitter @discovimmunol to keep up to date with the latest fundamental immunology research!
Immunotherapy Advances


Clinical & Experimental Immunology

Clinical & Experimental Immunology, Immunotherapy Advances and Discovery Immunology are the official journals of the British Society for Immunology. Profits derived from the sale of the journals are invested back into the BSI, providing major financial support for the Society's activities.
Support the BSI, submit your work now: